TuHURA Biosciences (HURA) Notes Payables (2017 - 2025)
TuHURA Biosciences (HURA) posted quarterly Notes Payables of $493386.0 for Q3 2025, up 13.68% quarter-over-quarter from $434000.0 in Q2 2025.
TuHURA Biosciences (HURA) Notes Payables (2017 - 2025) Analysis & Trends
TuHURA Biosciences' Notes Payables history runs 4 years deep, the most recent figure standing at $493386.0 for Q3 2025.
- In Q3 2025, Notes Payables changed N/A year-over-year to $493386.0; the TTM figure through Sep 2025 stood at $493386.0 (changed N/A YoY), while the FY2023 annual figure was $137000.0, changed N/A from the prior year.
- Notes Payables for Q3 2025 stood at $493386.0, up from $434000.0 in the prior quarter.
- The five-year high for Notes Payables was $493386.0 in Q3 2025, with the low at $137000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | TuHURA Biosciences | 37.61 Mn | 37.61 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 493,386.00 |
| Jun 30, 2025 | 434,000.00 |
| Dec 31, 2023 | 137,000.00 |
| Mar 31, 2018 | 5.00 |
| Dec 31, 2017 | 95.00 |
| Sep 30, 2017 | 589.00 |
| Jun 30, 2017 | 33,091.00 |
| Mar 31, 2017 | 157,145.00 |